Related Experiment Video

Updated: Jun 24, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Does imatinib turn recurrent and/or metastasized gastrointestinal stromal tumors into a chronic disease? - single

Thomas Armbrust1, Michael Sobotta, Bastian Gunawan

  • 1Department of Gastroenterology and Endocrinology, Georg-August-University of Göttingen, Germany.

European Journal of Gastroenterology & Hepatology
|April 17, 2009
PubMed
Abstract

Insights

This study on gastrointestinal stromal tumors (GIST) found that imatinib treatment resistance may be lower than previously reported. Specialized care may improve patient outcomes and compliance with imatinib therapy.

Area of Science:

  • Oncology
  • Gastroenterology
  • Pharmacology

Background:

  • Gastrointestinal stromal tumors (GIST) are mesenchymal tumors often driven by c-kit or PDGFRA mutations.
  • Imatinib is a targeted therapy inhibiting these mutations but resistance is a significant clinical challenge.
  • Reported imatinib resistance rates in GIST reach up to 50% within two years of treatment.

Purpose of the Study:

  • To analyze the treatment outcomes of 13 patients with relapsed or metastatic GIST receiving imatinib.
  • To evaluate the efficacy and resistance patterns of imatinib in a real-world clinical setting.

Main Methods:

  • Retrospective analysis of 13 consecutive GIST patients treated with imatinib.
  • Dosage adjustments (up to 800 mg daily) were made for some patients.
  • Outcomes including progression, stable disease, partial response, and overall survival were recorded.

Main Results:

  • The overall progression rate was 46% over a mean treatment duration of 53.5 months.
  • Four patients progressed and died despite dose escalation.
  • Two patients showed progressive disease late (46 and 52 months), while seven achieved stable disease or partial response.

Conclusions:

  • Imatinib resistance in GIST may occur less frequently than the reported 50% at 2 years.
  • Individualized treatment strategies in specialized centers could enhance patient compliance and potentially improve outcomes.
  • Long-term treatment with imatinib can be effective for a significant proportion of GIST patients.

More Related Videos

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...